Edwards Lifesciences is projected to deliver steady profit and revenue growth through 2026. Click here to read more on EW ...

Edwards Lifesciences (EW) stock and Medtronic (MDT) stock gain as Boston Scientific (BSX) halts sales of ACURATE heart valves ...

This was the stock's fourth consecutive day of gains.

Detailed price information for Edwards Lifesciences Corp (EW-N) from The Globe and Mail including charting and trades.

MedtechWOMEN today announced the theme of its upcoming MedtechVISION 2025 Annual Conference, "Revolution not Evolution: Medtech’s Next Chapter", signaling a bold call to action—urging the medtech ...

Investors responded positively to the news, boosting Edwards Lifesciences’ stock during the trading session. The company, which is a leading player in the heart valve market, may now face less ...

Edwards Lifesciences (NYSE:EW) saw its shares rise by 3% following news that competitor Boston Scientific (NYSE:BSX) is ...

A Relative Strength Rating upgrade for Edwards Lifesciences shows improving technical performance. Will it continue?

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Medical-device maker Edwards Lifesciences shares ticked up after rival Boston Scientific said it would stop selling its rival heart-valve replacement systems. The systems, called transcatheter aortic ...

Boston Scientific has discontinued global sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement ...

The cardiovascular devices market is projected to grow at a CAGR of ~7% over the forecast period. Major factors driving ...